Effect of ruxolitinib combined with glucocorticoid on cytomegalovirus activation in acute graft-versus-host disease
10.3760/cma.j.issn.0253-2727.2022.09.004
- VernacularTitle:芦可替尼联合糖皮质激素一线治疗急性移植物抗宿主病对巨细胞病毒激活的影响
- Author:
Shuangyi XING
1
;
Kun QIAN
;
Yingxin ZHAO
;
Bo PENG
;
Jingjing YANG
;
Liping DOU
;
Daihong LIU
Author Information
1. 解放军医学院、解放军总医院、解放军总医院第五医学中心血液病医学部，北京 100853
- Keywords:
Allogeneic hematopoietic stem cell transplantation;
Acute graft-versus-host disease;
Ruxolitinib;
Cytomegalovirus
- From:
Chinese Journal of Hematology
2022;43(9):732-737
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effect of ruxolitinib combined with glucocorticoid on cytomegalovirus (CMV) activation in patients with acute graft-versus-host disease (aGVHD) .Methods:The clinical data of 195 patients who underwent allogeneic hematopoietic stem cell transplantation in the Department of Hematology of the First Medical Center of the People’s Liberation Army General Hospital from August 2018 to September 2020 were retrospectively analyzed. According to the severity of aGVHD, the patients were divided into the non-GVHD group, aGVHD grade Ⅰ group, aGVHD grade Ⅱ-Ⅳ group, and aGVHD grade Ⅲ/Ⅳ group. In addition, they were classified into two subgroups according to the first-line treatment regimen for aGVHD: combined regimen group (ruxolitinib combined with glucocorticoid) and classical regimen group (glucocorticoid alone) . The cumulative incidence of CMV activation, the duration of CMV activation, and the duration of CMV negativity in each subgroup at 90 and 180 days after transplantation were analyzed. The overall survival and disease-free survival rates of patients in both regimens were compared.Results:Sixty-four (32.8%) patients in the group did not develop aGVHD. The numbers of patients with grade Ⅰ, Ⅱ-Ⅳ, and Ⅲ/Ⅳ aGVHD were 30 (15.4%) , 101 (51.8%) , and 14 (7.2%) , respectively. Compared with patients in the classical regimen, no significant difference was observed in the cumulative incidence of CMV activation, duration of CMV activation, and duration of CMV negativity in patients with grade Ⅰ-Ⅳ aGVHD in the combined regimen at 90 and 180 days after transplantation ( P>0.05) . Further analysis of patients with grade Ⅱ-Ⅳ and Ⅲ/Ⅳ aGVHD showed that the cumulative incidence of CMV activation, duration of CMV activation, and duration of CMV negativity did not show significant difference between the two treatment regimens ( P>0.05) . In addition, there was no significant difference in the overall survival and disease-free survival rates of patients in both regimens ( P>0.05) . Conclusion:Ruxolitinib combined with glucocorticoid as the first-line therapy for aGVHD did not increase the risk of CMV activation.
